Navigation Links
Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
Date:8/14/2012

etization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements  

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
2. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
3. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
4. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
5. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
6. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
7. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
8. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
9. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
10. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
11. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... States Food and Drug Administration ("FDA") said its primary results ... risk of blood clots for women who use drospirenone-containing birth ... safety of Yaz and Yasmin is the subject of approximately ... Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex ...
... BEACH, Calif., Sept. 27, 2011 For the third ... InformationWeek 500 annual listing of the nation,s most innovative ... honored for development and implementation of its Treatment ... communities real-time cost estimates specific to their coverage plan, ...
Cached Medicine Technology:FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 3
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , THURSDAY, Dec. 1 (HealthDay News) -- Posting ... processing plants on the Internet so it can be viewed ... report released Wednesday. The report is from the National ... advice on challenges facing the United States and the world. ...
... in the levels of two proteins involved in folding, ... destructive brain plaque found in Alzheimer,s disease, researchers report. ... specific positions to unleash their functions. When levels are ... normally dormant BACE1, a protein responsible for beta amyloid ...
... MD, a fourth-year resident in clinical and anatomic ... the highly coveted Resident Leadership Representative Award from ... demonstrating leadership and promoting ASCP membership and resident ... team led by Dr. Martin Kroll, won the ...
... (EGCG)a flavonoid found in green teainhibits the hepatitis C ... in the December issue of Hepatology , a ... Association for the Study of Liver Diseases, suggest that ... reinfection following liver transplantation. HCV infection can ...
... on chromosomes in human cervical cancer cells disrupts DNA ... and kills them more quickly, according to a study ... to like see their laboratory findings published in ... safer, more effective combination therapies for hard-to-treat pediatric brain ...
... December 1, 2011 -- Only 21 percent of surveyed medical ... when and when not to wash their hands in the ... issue of the American Journal of Infection Control , ... in Infection Control and Epidemiology. Three researchers from ...
Cached Medicine News:Health News:Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation 2Health News:Green tea flavonoid may prevent reinfection with hepatitis C virus following liver transplantation 2Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 2Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 3Health News:2 out of 3 medical students do not know when to wash their hands 2
... most other EMR,systems require you ... is the only,electronic patient charting,solution ... orthopaedic,workflow. Created around,five specific criteria ... clinic,OrthoPad allows you to see,more ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... EMS provides service to companies in many different ... and restaurants.There are no hidden charges at EMS ... and service are among the lowest in the ... of services ranging from MasterCard/Visa processing to Debit ...
Medicine Products: